Nektar Therapeutics financials
$59.24−1.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.1M | $10.9M | $21.8M | $11.8M | $11.2M | $10.5M | $29.2M | $24.1M | $23.5M | $21.6M | $23.9M | $24.1M |
| Gross profit | $10.1M | $10.9M | $21.8M | $11.8M | $11.2M | $10.5M | $21.2M | $19.7M | $13.7M | $13.1M | $16.6M | $11.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 72.7% | 81.6% | 58.5% | 60.6% | 69.5% | 48.5% |
| Operating income | -$42.3M | -$39.1M | -$27.7M | -$31.7M | -$36.2M | -$44.5M | -$26.0M | -$34.3M | -$49.8M | -$35.4M | -$33.5M | -$44.9M |
| Net income | -$40.6M | -$44.9M | -$36.1M | -$35.5M | -$41.6M | -$50.9M | $7.3M | -$37.1M | -$52.4M | -$36.8M | -$42.1M | -$45.8M |
| Net margin | −401.0% | −413.4% | −165.4% | −301.3% | −372.2% | −486.4% | 24.9% | −153.6% | −222.9% | −170.1% | −176.2% | −189.8% |
| Diluted EPS | $-1.23 | $-1.82 | $-1.77 | $-1.87 | $-2.95 | $-3.62 | $0.18 | $-2.66 | $-3.76 | $-2.85 | $-3.30 | $-3.60 |
| EBITDA | -$41.6M | -$38.1M | -$18.9M | -$31.3M | -$35.6M | -$43.9M | -$24.4M | -$33.3M | -$35.0M | -$32.8M | -$29.0M | -$31.8M |
| Operating cash flow | -$75.8M | -$44.3M | -$65.0M | -$48.8M | -$45.7M | -$49.1M | -$46.2M | -$43.9M | -$37.7M | -$47.9M | -$47.0M | -$42.1M |
| Free cash flow | -$75.9M | -$44.3M | -$65.0M | -$48.9M | -$45.8M | -$49.1M | -$46.6M | -$44.6M | -$37.9M | -$48.0M | -$47.3M | -$42.2M |
| Diluted shares | 33.1M | 24.7M | 20.4M | 18.9M | 14.1M | 14.1M | 40.0M | 13.9M | 13.9M | 13.0M | 12.7M | 12.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $39.3M | $149.6M | $15.1M | $41.0M | $43.0M | $38.9M |
| Short-term investments | $645.1M | $419.0M | $230.6M | $229.2M | $132.9M | $179.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.10B | $763.3M | $280.4M | $301.3M | $207.5M | $256.2M |
| Total liabilities | $192.0M | $187.1M | $190.6M | $216.3M | $231.7M | $242.5M |
| Shareholders' equity | $903.1M | $576.2M | $89.8M | $85.1M | -$24.2M | $13.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology